Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.50 |
| ▸ | STS | P08842 | 3/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30307823 | 1.00 | GPR119 (0.50) | GPR119STSDPP4MMP13CHRNA7 | |
| SCHEMBL20502297 | 1.00 | GPR119 (0.50) | GPR119STSDPP4MMP13CHRNA7 | |
| SCHEMBL23620971 | 0.90 | GPR119 (0.43) | GPR119CHRNA7 | |
| SCHEMBL20502304 | 0.85 | GPR119 (0.54) | GPR119 | |
| SCHEMBL23620950 | 0.85 | GPR119 (0.54) | GPR119DPP4 | |
| SCHEMBL23620941 | 0.84 | GPR119 (0.46) | GPR119STSMMP13 | |
| SCHEMBL20502327 | 0.84 | CA1 (0.39) | — | |
| SCHEMBL23620959 | 0.84 | CA1 (0.39) | — | |
| SCHEMBL20502574 | 0.80 | GPR119 (0.52) | GPR119STSDPP4MMP13 | |
| SCHEMBL23620938 | 0.80 | GPR119 (0.52) | GPR119STSDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3596059-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS DUAL ATX/CA INHIBITORS | HOFFMANN LA ROCHE (CH) | 2024-04-24 | — | — | EP | disclosed |
| CN-110392679-B | Heterocyclic compounds useful as dual ATX/CA inhibitors | 豪夫迈·罗氏有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-11059794-B2 | Heterocyclic compounds useful as dual ATX/CA inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059794-B2 | Heterocyclic compounds useful as dual ATX/CA inhibitors | ATXN2, ATXN2L, ATXN10 | GPR119 3054/4885STS 3566/4885DPP4 2754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.